Project Grant K08CA312446
Award Date 7/3/26
Completion Date 6/30/31
Dollars Obligated $238K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $680,598 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, with a completion date of August 31, 2030. The award supports fundamental research focused on decoding the Cullin-5 (CUL5) E3 ubiquitin ligase complex to engineer therapeutic T cells with enhanced durability and sustained effector function. The project...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $680,597 to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, for a five-year project extending through March 31, 2031. The project focuses on developing and executing genome-wide CRISPR loss-of-function screens in human CD4+ and CD8+ T cells to identify G protein-coupled receptor (GPCR) pathway targets that enhance chimeric antigen...
- The National Cancer Institute awarded the University of Southern California $137,459 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to support structured research training and workforce development in cancer immunotherapy. The award funds a K01 career development grant focused on developing a spatially controlled priming system for chimeric antigen receptor (CAR) T cell therapy in solid tumors using focused ultrasound technology. The research deliverables include...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a project grant of $151,040 under the Cancer Research Manpower program (CFDA 93.398) effective January 1, 2026, with completion scheduled for July 31, 2028. The award supports a research initiative titled "Toward Understanding the Functional Landscape of Proteolysis at the Cell Surface," which aims to develop advanced analytical methods and chemical...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center, effective May 1, 2026 through April 30, 2031, under the Cancer Biology Research program (CFDA 93.396). This research grant funds a five-year investigative study entitled "Control of T-Cell Stemness and T-Cell Exhaustion by KEAP1-NRF2 Axis," which will be conducted at the institution's Dallas, Texas campus. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $648,626 to the University of California, Irvine, effective April 2, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically how programmed death receptor 1 (PD-1) blockade affects tumor microenvironments. The research seeks to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $658,722 to the University of California, San Francisco (UCSF) under the Cancer Treatment Research program (CFDA 93.395) beginning March 12, 2026 and extending through February 28, 2031. The project, titled "The Enabler of Tumor Cell Immortality in TERT Promoter Mutant Cancers," focuses on elucidating the molecular mechanisms by which telomerase reverse transcriptase (TERT) promoter mutations...